Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue
Launched by DARYOUSH HAMIDI ALAMDARI, PHD · Jun 6, 2024
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
This pilot clinical trial recruited 19 patients at Imam Reza Hospital in Mashhad, Iran (2023) who had developed unilateral or bilateral refractory postoperative effusion resistant to conventional thoracostomy treatment. Treatment success was defined as effusion \<50 ml/day after 48 hours, along with symptomatic improvement and no adverse events.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of pleural effusion after cardiac surgery in open-heart surgery
- • patients who sign an informed consent form
- Exclusion Criteria:
- • Hemodynamically unstable patients
- • Patients who did not sign an informed consent form
About Daryoush Hamidi Alamdari, Phd
Dr. Daryoush Hamidi Alamdari, PhD, is a distinguished clinical trial sponsor with extensive expertise in the design and execution of innovative research studies. With a strong academic background and a commitment to advancing medical knowledge, Dr. Alamdari leads initiatives that aim to evaluate novel therapies and enhance patient outcomes. His collaborative approach fosters partnerships with healthcare professionals and research institutions, ensuring rigorous adherence to ethical standards and regulatory compliance throughout the trial process. Dr. Alamdari’s dedication to scientific excellence and patient-centered research positions him as a key contributor to the advancement of clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mashhad, Razavi Khorasan, Iran, Islamic Republic Of
Patients applied
Trial Officials
Daryoush Hamidi-Alamdari, Ph.D
Study Chair
Mashhad university of medical sience
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported